Search
Eflornithine
go.drugbank.com/drugs/DB06243ApprovedInvestigationalWithdrawnpatients with high-risk neuroblastoma who have demonstrated at least a partial response to prior multiagent, multimodality therapy, including anti-GD2 immunotherapy. … [A262823,L49318] Subsequently, on December 14, 2023, the FDA approved eflornithine again but under the brand name IWILFIN as an oral maintenance therapy to reduce the risk of relapse in adult and pediatric
Potassium chloride
go.drugbank.com/drugs/DB00761ApprovedInvestigationalWithdrawnproducts containing potassium chloride that supply 100 mg or more of potassium per dosage unit, except for controlled-release dosage forms and those products formulated for preparation of solution prior to
Mixtures: Potassium Chloride 0.3% w/v and Glucose 5% w/v Intravenous Infusion BP, Potassium Chloride 0.15% w/v and Glucose 5% w/v Intravenous Infusion BPProducts: Potassium Chloride Injection Demo 10% W/V, POTAXINE INJECTION 10% W/V (10ML AMPOULE)Atovaquone
go.drugbank.com/drugs/DB01117ApprovedInvestigationalAtovaquone is a hydroxynaphthoquinone, or an analog of ubiquinone, that has antimicrobial and antipneumocystis activity. It is being used in antimalarial protocols.
Mixtures: ATOVAQUONE E PROGUANILE MYLAN GENERICS, ATOVAQUONE E PROGUANILE MYLAN GENERICSObeticholic acid
go.drugbank.com/drugs/DB05990ApprovedInvestigationalhepatic decompensation) due to a risk of liver failure, in some cases requiring liver transplantation. … [A192786] Obeticholic acid is a farnesoid-X receptor (FXR) agonist used to treat this condition, possibly allowing for increased survival.
Colestipol
go.drugbank.com/drugs/DB00375ApprovedF4555, F4567, L6262] In particular, as colestipol's general mechanism of action ultimately results in the decreased absorption and enhanced secretion of bile acids and lipids in the feces, patients who … take complicated medication regimens, experience constipation or biliary obstruction, etc. may not be good candidates for using the agent owing to its physical effects on the gut.
Vinflunine
go.drugbank.com/drugs/DB11641ApprovedInvestigationalVinflunine is a microtubule inhibitor that binds to tubulin at or near to the vinca binding sites to inhibits its polymerization into microtubules during cell proliferation [L1396]. … Having an incidence of 429,700 new cases per year worldwide, urothelial carcinoma of the bladder is one of the most common malignancies that mostly affects individuals aged 50–79 years [A32626].
Olezarsen
go.drugbank.com/drugs/DB18728ApprovedInvestigational[A264888,A264893] Olezarsen is conjugated to a ligand containing three N-acetyl-galactosamine (GalNAc) residues to enable its delivery to hepatocytes. … [A264888] Olezarsen works to reduce the plasma triglyceride levels by reducing APOC3 production.
Synonyms: DNA, D(P-THIO)((2'-O-(2-METHOXYETHYL))RA-(2'-O-(2-METHOXYETHYL))RG-(2'-O-(2-METHOXYETHYL))M5RC-(2'-O-(2-METHOXYETHYL))M5RU-(2'-O-(2-METHOXYETHYL))M5RU-M5C-T-T-G-T-M5C-M5C-A-G-M5C-(2'-O-(2-METHOXYETHYL), )M5RU-(2'-O-(2-METHOXYETHYL))M5RU-(2'-O-(2-METHOXYETHStem bromelain
go.drugbank.com/drugs/DB12249ApprovedThis action allows bromelain to demonstrate a wide range of therapeutic benefits ranging from cardiovascular to anticancer therapy - but the specific mechanisms of action by which it can elicit these effects … Bromelain itself belongs to a category of protein-digesting enzymes that are obtained commercially from the fruit or stem of pineapples [A27198].
Eliglustat
go.drugbank.com/drugs/DB09039ApprovedInvestigationalThere are no dosing recommendations for CYP2D6 ultra-rapid or indeterminate metabolizers. … In patients with Gaucher disease, the accumulation of glucosylceramide leads to the formation of Gaucher cells that infiltrate the liver, spleen, bone marrow and other organs.
Insulin degludec
go.drugbank.com/drugs/DB09564ApprovedInvestigationalto endogenous insulin, and in the long term, damage to pancreatic islet cells. … pancreatic cells that the body is no longer able to produce insulin on its own.